Applied Filters
AbbVie says bar for ‘sham litigation’ is too low
AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.
AbbVie, Taro settle over rosacea drug patents
AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.
SCOTUS declines patents review on Enbrel drug
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
Patent litigation: a global perspective
Patent protection is a global affair, so if you find yourself embroiled in litigation, it helps to know what benefits and challenges different jurisdictions can offer.
US Tax Court says Mylan can deduct patent litigation fees
Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court.
UK High Court upholds Alcon glaucoma patent
The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23.
Pfizer drops Xeljanz patent suits
Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Fifth circuit denies Impax pay-for-delay petition
The Fifth Circuit of the Court of Appeals has denied a petition from Impax Laboratories to overturn a decision finding Impax engaged in an illegal pay-for-delay settlement with Endo Pharmaceuticals.
Repurposed drugs: protections and incentives
Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
